The Efficacy of Presurgical Therapy With Avelumab and Axitinib for Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus

Clin Genitourin Cancer. 2023 Oct;21(5):613.e1-613.e6. doi: 10.1016/j.clgc.2023.04.010. Epub 2023 Apr 28.

Affiliations

¹ Department of Urology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
² Department of Urology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan. Electronic address: daatera0804@yahoo.co.jp.
³ Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan.

PMID: 37236863
DOI: 10.1016/j.clgc.2023.04.010

No abstract available

Keywords: Immune checkpoint inhibitor; Kidney cancer; Neoadjuvant therapy; Targeted molecular therapy; Thrombosis.

Publication types

Case Reports

MeSH terms

Axitinib / therapeutic use
Carcinoma, Renal Cell* / pathology
Humans
Kidney Neoplasms* / pathology
Nephrectomy
Thrombectomy
Vena Cava, Inferior / pathology
Vena Cava, Inferior / surgery
Venous Thrombosis* / drug therapy

Substances

Axitinib
avelumab